title: Rituximab is effective in severe treatment-resistant neurological Behçet's syndrome.
abstract: The objective of this study is to describe a case of severe and treatment-resistant neurological Behçet's syndrome responsive to a novel therapy. This case report describes the patient who failed to respond to conventional therapy but the brain stem lesion resolved with the anti-CD20 biological agent rituximab. Neurological complications are uncommon in Behçet's syndrome; 80% involve a meningoencephalitis which can be severe and relapsing. This is the first report of effectiveness of rituximab in this uncommon disease.
authors.affiliation: Department of Clinical Neurosciences, Royal Free Hospital, Pond Street, London, NW3 2QG, UK. d.kidd@ucl.ac.uk.|Behçet's Syndrome Centre of Excellence, Dental Institute, Royal London Hospital, Whitechapel, London, E1 1BB, UK. d.kidd@ucl.ac.uk.
authors.forename: D P
authors.initials: DP
authors.lastname: Kidd
mesh_terms: D000328:Adult; D001528:Behcet Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000494:pharmacology*; D000069283:Rituximab / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D007155:Immunologic Factors; D000069283:Rituximab
keywords: Behçet’s syndrome; Neurological; Rituximab; Treatment